ONCOVIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONCOVIN is a small-molecule injectable anticancer agent approved in 1963 by Eli Lilly and Company. The specific mechanism of action and indicated malignancies are not documented in available data, though the product's 60+ year history suggests established use in oncology. As a legacy injectable chemotherapy, it represents a foundational class in cancer treatment.
LOE Approaching
Approaching loss of exclusivity signals contraction of brand team and shift toward lifecycle management or product exit strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Started Apr 2011
43 enrolled
Richter's Syndrome
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Started Jul 2007
787 enrolled
B-cell Lymphoma
Career Relevance
ONCOVIN offers limited career growth potential given its LOE-approaching status and minimal linked job openings. Positions on this product are typically maintenance-focused, suited for professionals seeking stability in a legacy asset or transition roles within oncology.
Worked on ONCOVIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.